Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma

European Journal of Clinical Investigation

Volumn 33, Issue 5, 2003, Pages 420-425

  Ribatti, Domenico ^a   Ennas, M G ^b   Vacca, A ^a   Ferreli, F ^b   Nico, B ^a   Orru, S ^c   Sirigu, P ^b  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c Oncology Hospital   (Italy)

Author keywords

Angiogenesis; Mast cells; Melanoma; Prognosis; Tryptase

Indexed keywords

BLOOD CLOTTING FACTOR 8; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY AA1; MONOCLONAL ANTIBODY M616; TRYPTASE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANGIOGENESIS; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; LYMPH NODE METASTASIS; MALE; MAST CELL; MELANOMA; METASTASIS; MICROVASCULATURE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; TUMOR GROWTH; TUMOR VASCULARIZATION;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MAST CELLS; MELANOMA; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; PROSPECTIVE STUDIES; SERINE ENDOPEPTIDASES; TRYPTASES;

EID: 0037569416     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2003.01152.x     Document Type: Article

References (32)

1. Weidner N. Intratumoral microvessel density as a prognostic factor in cancer. Am J Pathol 1995;147:9-19.
2. Srivastava A, Laidler P, Davies RP, Horgan K, Hughes LE. The prognostic significance of tumor vascularity in intermediate-thickness (0.76-4.0 mm thick) skin melanomas. Am J Pathol 1988;113:419-23.
3. Srivastava A, Hughes LE, Woodcock JP, Laidler P. Vascularity in cutaneous melanoma detected by Doppler sonography and histology: correlation with tumor behaviour. Br J Cancer 1989;59:89-91.
4. Smolle J, Soyer HP, Hofman-Wellenhof R, Smolle-Juttner FM, Kerl H. Vascular architecture of melanocytic skin tumors: a quantitative immunohistochemical study using automated image analysis. Pathol Res Pract 1989;185:740-5.
5. Followfield ME, Cook MG. The vascularity of primary cutaneous melanoma. J Pathol 1991;164:241-4.
6. Barnhill RL, Fandrey K, Levy MA, Mihm MC Jr, Hyman B. Angiogenesis and tumor progression of melanoma. Quantification of vascularity in melanocytic nevi and cutaneous malignant melanoma. Lab Invest 1992;67:331-7.
7. Barnhill RL, Levy MA. Regressing thin cutaneous malignant melanomas (< or = 1.0 mm) are associated with angiogenesis. Am J Pathol 1993;143:99-104.
8. Busam KJ, Berwick M, Blessing K, Fandrey K, Kang S, Karaoli T et al. Tumor vascularity is not a prognostic factor for malignant melanoma of the skin. Am J Pathol 1995;147:1049-56.
9. Straume O, Salveson HB, Aksel LA. Angiogenesis is prognostically important in vertical growth phase of melanoma. Int J Oncol 1999;15:595-9.
10. Kashani-Sabet M, Sagebiel RW, Ferreira CMM, Nosrati M, Miller JR III Tumor vascularity in the prognostic assessment of primary cutaneous melanoma. J Clin Oncol 2002;20:1826-31.
11. Ribatti D, Vacca A, Nico B, Crivellato E, Roncali L, Dammacco F. The role of mast cells in tumour angiogenesis. Br J Haematol 2001;115:514-21.
12. Ribatti D, Nico B, Vacca A, Marzullo A, Calvi N, Roncali L et al. Do mast cells help to induce angiogenesis in B-cell non-Hodgkin's lymphomas? Br J Cancer 1998;77:1900-6.
13. Ribatti D, Vacca A, Nico B, Quondamatteo F, Ria R, Minischetti M, Marzullo A et al. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. Br J Cancer 1999;79:451-5.
14. Ribatti D, Vacca A, Marzullo A, Nico B, Ria R, Roncali L et al. Angiogenesis and mast cell density with tryptase activity increase simultaneously with pathological progression in B-cell non Hodgkin's lymphomas. Int J Cancer 2000;85:171-5.
15. Ribatti D, Polimeno G, Vacca A, Marzullo A, Crivellato E, Nico B et al. Correlation of bone marrow angiogenesis and mast cell density with tryptase activity in myelodysplastic syndromes. Leukemia 2002;16:1680-4.
16. Ribatti D, Vacca A, Ria R, Marzullo A, Nico B, Filotico R et al. Neovascularisation, expression of fibroblast growth factor-2, and mast cell with tryptase activity increase simultaneously with pathological progression in human malignant melanoma. Eur J Cancer 2003;39:666-74.
17. Clark WH, Elder DE, Guerry D, Braitman LE, Trock BJ, Schultz D et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989;81:1893-904.
18. Vacca A, Ribatti D, Roncali L, Lospalluti M, Serio G, Carrel S et al. Melanocyte tumor progression is associated with changes in angiogenesis and expression of the 67-kilodalton laminin receptor. Cancer 1993;72:455-61.
19. Ribatti D, Presta M, Vacca A, Ria R, Giuliani R, Dell'Era P et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 1999;93:2627-36.
20. Vacca A, Ribatti D, Presta M, Minischetti M, Iurlaro M, Ria R et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999;93:3064-73.
21. Vacca A, Iurlaro M, Ribatti D, Minischetti M, Nico B, Ria R et al. Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 1999;94:4143-55.
22. Elias H, Hyde DM. Stereological measurements of isotropic structures. In: Elias H, Hyde DM, editors. A Guide to Practical Stereology. Basel: Karger;1983.pp. 25-44.
23. Park CC, Bissell MJ, Barcellos-Hoff MH. The influence of the microenvironment on the malignant phenotype. Mol Med Today 2000;6:324-9.
24. Blair RJ, Meng H, Marchese MJ, Ren S, Schwartz LB, Tonnesen MG et al. Human mast cells stimulate vascular tube formation. Tryptase is a novel, potent angiogenic factor. J Clin Invest 1997;99:2691-700.
25. Stack MS, Johnson DA. Human mast cell tryptase activates single-chain urinary-type plasminogen activator (pro-urokinase). J Biol Chem 1994;269:9416-9.
26. Toth T, Toth-Jakatics R, Jimi S, Takebayashi S, Kawamoto N. Cutaneous malignant melanoma: correlation between neovascularization and peritumoral accumulation of mast cells overerexpressing vascular endothelial growth factor. Hum Pathol 2000;31:955-60.
27. Nakanishi H, Oguri K, Takenaga K, Hosada S, Okayama M. Differential fibrotic stromal responses of host tissue to low- and high-metastatic cloned Lewis lung carcinoma cells. Lab Invest 1994;70:324-32.
28. Farram E, Nelson DS. Mouse mast cells as anti-tumor effector cells. Cell Immunol 1980;55:294-301.
29. Henderson WR, Chi EY, Yong EC, Klebanoff SJ. Mast cell-mediated tumor cell cytotoxicity: role of the peroxidase system. J Exp Med 1981;153:520-33.
30. Kessler DA, Langer RE, Pless NA, Folkman J. Mast cells and tumour angiogenesis. Int J Cancer 1976;18:703-9.
31. Starkey JR, Crowle PK, Taubenberger S. Mast-cell-deficient W/W mice exhibit a decreased rate of tumor angiogenesis. Int J Cancer 1988;42:48-52.
32. Dethlefsen SM, Matsuura N, Zetter BR. Mast cell accumulation at sites of murine tumor implantation: implications for angiogenesis and tumor metastasis. Invasion Met 1994;14:395-408.